130 related articles for article (PubMed ID: 32439154)
1. Hepatosplenic T-cell lymphoma (HSTCL) in patient with Crohn's disease treated with azathioprin.
Soria-López E; Casanova-Espinosa M; Fernández Pérez F
Med Clin (Barc); 2021 Jun; 156(11):579-580. PubMed ID: 32439154
[No Abstract] [Full Text] [Related]
2. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.
Ochenrider MG; Patterson DJ; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):144-8. PubMed ID: 20371449
[TBL] [Abstract][Full Text] [Related]
3. Hepatosplenic T-cell lymphoma in a 47-year-old Crohn's disease patient on thiopurine monotherapy.
van de Meeberg MM; Derikx LA; Sinnige HA; Nooijen P; Schipper DL; Nissen LH
World J Gastroenterol; 2016 Dec; 22(47):10465-10470. PubMed ID: 28058028
[TBL] [Abstract][Full Text] [Related]
4. Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.
Selvaraj SA; Chairez E; Wilson LM; Lazarev M; Bass EB; Hutfless S
Syst Rev; 2013 Jul; 2():53. PubMed ID: 23826928
[TBL] [Abstract][Full Text] [Related]
5. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?
Rosh JR; Gross T; Mamula P; Griffiths A; Hyams J
Inflamm Bowel Dis; 2007 Aug; 13(8):1024-30. PubMed ID: 17480018
[TBL] [Abstract][Full Text] [Related]
6. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease.
Drini M; Prichard PJ; Brown GJ; Macrae FA
Med J Aust; 2008 Oct; 189(8):464-5. PubMed ID: 18928444
[TBL] [Abstract][Full Text] [Related]
7. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy.
Zeidan A; Sham R; Shapiro J; Baratta A; Kouides P
Leuk Lymphoma; 2007 Jul; 48(7):1410-3. PubMed ID: 17613771
[No Abstract] [Full Text] [Related]
8. [Successful cord blood transplantation for refractory gamma-delta hepatosplenic T-cell lymphoma developed during treatment of Crohn's disease].
Saito A; Nara M; Fujishima T; Kuroki W; Yamashita T; Kobayashi T; Ikeda S; Kitadate A; Kameoka Y; Takahashi N
Rinsho Ketsueki; 2024; 65(1):41-46. PubMed ID: 38311388
[TBL] [Abstract][Full Text] [Related]
9. Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree?
Moran G; Dillon J; Green J
Inflamm Bowel Dis; 2009 Sep; 15(9):1281-2. PubMed ID: 19067412
[No Abstract] [Full Text] [Related]
10. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease.
Beigel F; Jürgens M; Tillack C; Subklewe M; Mayr D; Göke B; Brand S; Ochsenkühn T
Nat Rev Gastroenterol Hepatol; 2009 Jul; 6(7):433-6. PubMed ID: 19575026
[TBL] [Abstract][Full Text] [Related]
11. How Does It Look in an Autopsy? Hepatosplenic T-Cell Lymphoma in a Patient with Crohn’s Disease on Azathioprine.
Rastogi P; Nada R
Turk J Haematol; 2020 Aug; 37(3):205-206. PubMed ID: 32270949
[No Abstract] [Full Text] [Related]
12. Hepatosplenic lymphoma presenting initially as hemophagocytic syndrome in a 21-year-old man with Crohn's disease: a case report and literature review.
Côté-Daigneault J; Bernard EJ
Can J Gastroenterol; 2011 Aug; 25(8):417-8. PubMed ID: 21912765
[No Abstract] [Full Text] [Related]
13. The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006.
Herrinton LJ; Liu L; Abramson O; Jaffe ES
Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):49-52. PubMed ID: 21823196
[TBL] [Abstract][Full Text] [Related]
14. Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?
Subramaniam K; Yeung D; Grimpen F; Joseph J; Fay K; Buckland M; Talaulikar D; Elijah J; Clarke AC; Pavli P; Moore J
Intern Med J; 2014 Mar; 44(3):287-90. PubMed ID: 24621284
[TBL] [Abstract][Full Text] [Related]
15. Pancytopenia in a Young Male Patient With Inflammatory Bowel Disease.
Jansson-Knodell CL; Walker MJ; Fischer M
Gastroenterology; 2021 Apr; 160(5):1483-1485. PubMed ID: 32777287
[No Abstract] [Full Text] [Related]
16. Hepatosplenic gammadelta-T-cell lymphoma with leukemic course after renal transplantation.
Steurer M; Stauder R; Grünewald K; Gunsilius E; Duba HC; Gastl G; Dirnhofer S
Hum Pathol; 2002 Feb; 33(2):253-8. PubMed ID: 11957154
[TBL] [Abstract][Full Text] [Related]
17. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.
Parakkal D; Sifuentes H; Semer R; Ehrenpreis ED
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1150-6. PubMed ID: 21941193
[TBL] [Abstract][Full Text] [Related]
18. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.
Shah ED; Coburn ES; Nayyar A; Lee KJ; Koliani-Pace JL; Siegel CA
Aliment Pharmacol Ther; 2020 Mar; 51(5):527-533. PubMed ID: 31990422
[TBL] [Abstract][Full Text] [Related]
19. Hepatosplenic T-cell lymphoma in a young immunocompetent man.
Petrova M; Gomes MM; Carda JP; Pereira de Moura J
BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 27033291
[TBL] [Abstract][Full Text] [Related]
20. Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors.
Yabe M; Miranda RN; Medeiros LJ
Hum Pathol; 2018 Apr; 74():5-16. PubMed ID: 29337025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
